Drugs / DR30303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05639153 | May 2022 → Dec 2025 | digestive system cancer | Zhejiang Doer Biologics Co., Ltd. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-01 | Zhejiang Doer Biologics Co., Ltd. | Results 道尔生物将在2022年AACR年会上披露靶向CLDN18.2单域抗体DR30303临床前数据 doerbio.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-01 | Zhejiang Doer Biologics Co., Ltd. | 道尔生物将在2022年AACR年会上披露靶向CLDN18.2单域抗体DR30303临床前数据 doerbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DR30303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639153 ↗ |
| Modality | Monoclonal antibody | “DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2).” NCT05639153 ↗ |
| Route | Intravenous | “DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1” NCT05639153 ↗ |